Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Memorial Sloan Kettering Cancer Center
EMD Serono
National Cancer Institute (NCI)
OncoSec Medical Incorporated
Ludwig Institute for Cancer Research
Incyte Corporation
Dana-Farber Cancer Institute
Medical University of Graz